As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.
The antifungal, sertaconazole (Ertaczo, Valeant, others), was no better than the topical vehicle placebo in a well controlled, multicenter trial to treat unremitting pruritus in atopic dermatitis (AD).
As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.
As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.